Business
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
-Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -FDA clearance granted for Investigational New Drug (IND) application for
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":"\n-Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023-\n-FDA clearance granted for Investigational New Drug (IND) application for EGFR-TRACTr (JANX008)-\n-$327.0 million in year-end cash and cash equivalents and short-term investments-\n\n SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.\n\n“Janux made great strides in 2022 as we transitioned to a clinical-stage company by dosing the first patient with our PSMA-TRACTr and advancing our pipeline utilizing our novel TRACTr and TRACIr platforms. We recently received IND clearance from the FDA for our EGFR-TRACTr, keeping us on track to enter a second program into the clinic. Importantly, this milestone underscores our ability to reproducibly bring novel immunotherapies through development and deliver them to patients. Two of our core values at Janux are ‘collaboration’ and ‘urgency,’ and both were on display in connection with hitting these milestones,” said David Campbell, Ph.D., President and CEO of Janux.\n\nRECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:\n\nJanux has prioritized its programs to enable sufficient funding to provide key clinical data assessments for its lead programs. Janux is aware of recent media reports related to the closure of Silicon Valley Bank (“SVB”). Janux considers its exposure to any liquidity concern at SVB as immaterial and will have no impact on its short- or long-term objectives. In addition, none of Janux’s investment portfolio contains direct exposure to SVB.\n\n\nLead program PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in prostate cancer patients.\n\n\nJanux received U.S. Food and Drug Administration (FDA) clearance for an IND application for EGFR-TRACTr (JANX008).\n\n\nPD-L1xCD28 TRACIr (JANX009) on-track for an IND submission in 2023.\n\n\nTROP2-TRACTr evaluations to support development candidate selection are ongoing.\n\n\nJanux anticipates providing an interim clinical update from the PSMA-...